Novo Nordisk stock slipped 1.2% to 69.30. Novo Nordisk Is On A Licensing Spree. This is the second big weight-loss deal from Novo ...

A novel islet cell therapy delivered through a single infusion lowered HbA1c and eliminated severe hypoglycemia events for ...

Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry. As the ...

The company has a debt-to-equity ratio of 0.23, a current ratio of 2.50 and a quick ratio of 1.53. Hawkins, Inc. has a 1-year low of $69.92 and a 1-year high of $139.55. Hawkins (NASDAQ ...

To make matters worse, on March 10, 2025, Novo Nordisk reported its CagriSema Phase 3 REDEFINE 2 CagriSema late-stage study revealed just 13.7% weight loss versus 3.1% placebo in overweight type 2 ...